Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MakeMyTrip Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $225 (market cap $29.97B), while MakeMyTrip Ltd trades at $60.31 (market cap $5.68B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.3× MakeMyTrip Ltd's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MMYT | |
|---|---|---|
Market Cap | $29.97B | $5.68B |
Sector | Health | Technology |
52-Week High | $491.22 | $103.21 |
52-Week Low | $205.48 | $36.30 |
Enterprise Value | $27.93B | $6.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
MakeMyTrip (MMYT) trades at $60.31, down 0.99% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth to $978M in 2025 and consistent earnings beats, though Q2 2026 missed expectations. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target. Recent news highlights travel industry momentum despite temporary air-ticketing softness.
Investment outlook appears favorable with strong fundamentals and bullish analyst consensus, though risks include rising debt levels and geopolitical travel disruptions. The stock's high P/E ratio of 267 requires sustained earnings growth to justify valuation. Recent institutional selling by Boston Common Asset Management warrants monitoring for broader sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
